Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy. Here's what we know so far about this promising new option for those ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...

The percentage of participants who achieved at least 25% weight loss was 34.7% in the CagriSema group, 14.8% in the semaglutide group and 6.5% in the cagrilintide group, while the percentage that ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.

CagriSema-treated patients achieved a superior weight loss of 13.7% vs 3.4% with placebo. Notably, at the end of the trial, 61.9% of patients treated with CagriSema were on the highest dose.

As Healio previously reported in December, CagriSema (Novo Nordisk) conferred a 22.7% weight loss at 68 weeks among adults with obesity and without diabetes in the REDEFINE 1 trial. In News News ...

When evaluating under the trial product estimand, findings showed CagriSema-treated patients achieved a superior weight loss of 22.7% compared with 11.8% with cagrilintide 2.4mg, 16.1% with ...

CagriSema patients lost more weight than those taking either component alone: 20.4% for the combination vs 11.5% with cagrilintide, 14.9% with semaglutide, and 3% with placebo.

In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...